RARITAN, N.J., September 29, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the initiation of its Phase 3 EVERGREEN study. The study will evaluate the efficacy, safety and immunogenicity of Janssen's investigational adult vaccine against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), when compared with placebo in

NEW BRUNSWICK, N.J., September 21, 2021 - Johnson & Johnson (NYSE: JNJ) (the Company) today announced new data reinforcing the strong and long-lasting protection of its COVID-19 vaccine. New data also showed that protection against COVID-19 increases when a booster shot of the Johnson & Johnson vaccine is administered. The safety profile of the vaccine

The Anima Research Center, currently the largest research center in the world where the Janssen vaccine is tested on humans, is opening a new site at UHasselt's Science Park. The new research center will increase the testing capacity for new vaccines. For example, the team will soon start developing a new vaccine against the RSV virus.

It is an illusion to think that we will be rid of it with one or two shots. Perhaps certainly the weak will have to be vaccinated again next year. So says Dr. Erik Buntinx. He heads the Anima Research Center in Alken, currently the largest research center in the world where the Janssen vaccine is being tested.

It is an illusion to think that one or two vaccinations will get us through. The weaker ones will probably have to be vaccinated again next year. So says doctor Erik Buntinx. He heads the Anima Research Center in Alken, currently the largest research centre in the world where the Janssen vaccine is being tested on people.

Doctor Erik Buntinx of the Alken research centre Anima is delighted that he and his team can contribute to the war effort to find a good vaccine.

The shipment of vaccines is from Johnson and Johnson, which is having them tested on a large number of test subjects in Alken. "The unique thing about the vaccine is that it will only need to be administered once".

In Alken, 1 000 people will receive the Johnson & Johnson corona vaccine this week. This is the third test phase of the vaccine, which will be ready in the course of the spring.

The PROVENT study is investigating a combination of two experimental monoclonal antibodies for the prevention of COVID-19. The study drug has not yet been approved by regulatory agencies and can only be given to humans as part of a clinical research study

ARC will soon start testing two candidate vaccines against corona and an alternative treatment method for corona patients.
As part of this study, the ANIMA Research Centre received a visit from TVL.